Moerae Matrix is a privately held biopharmaceutical company focused on the development of first-in-class targeted therapeutics for fibrotic disease. Based on proprietary technology from Purdue University, the company is advancing a suite of peptide therapeutics that target MAPKAP kinase 2 (MK2), a key terminal kinase in the TGF-beta/p38 pathway, with a high degree of specificity. Moerae Matrix’s first development candidate, MMI-0100, shows excellent activity in multiple models of fibrosis, including the bleomycin model of pulmonary fibrosis, in which MMI-0100 uniquely demonstrates potent anti-fibrotic activity even when administered days after the onset of injury. The compound has an excellent preclinical toxicology profile and is IND-ready for clinical development in acute fibrotic indications. Preclinical development is also underway with a pulmonary delivery formulation of MMI-0100 for chronic treatment of idiopathic pulmonary fibrosis (IPF).
Moerae Matrix has assembled an experienced management team which operates via a virtual, highly capital efficient model. The company completed a Series A financing in 2010 and has also successfully leveraged multiple sources of non-dilutive capital to support MMI-0100’s advancement. In addition to its seasoned board of directors, Moerae Matrix has aggregated a world-class network of pulmonary fibrosis advisors and collaborators to support the development of this potentially breakthrough therapeutic.